The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations

This publication has 50 references indexed in Scilit:

• NKF-DOQI clinical practice guidelines for peritoneal dialysis adequacy
  American Journal of Kidney Diseases, 1997
• Renal Anaemia Treatment with Recombinant Human Erythropoietin Increases Cardiac Output in Patients with Ischaemic Heart Disease
  Scandinavian Journal of Urology and Nephrology, 1996
• A Multidisciplinary Intervention to Prevent the Readmission of Elderly Patients with Congestive Heart Failure
  New England Journal of Medicine, 1995
• Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles
  The American Journal of Cardiology, 1994
• Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones.
  Heart, 1993
• Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin
  American Heart Journal, 1992
• The Erythrocyte Sedimentation Rate in Congestive Heart Failure
  New England Journal of Medicine, 1991
• Therapy with Recombinant Human Erythropoietin Reduces Cardiac Size and Improves Heart Function in Chronic Hemodialysis Patients
  American Journal of Nephrology, 1991
• Precipitating Factors Leading to Decompensation of Heart Failure
  Archives of internal medicine (1960), 1988
• Multivariate analysis using a linear discriminant function for predicting the prognosis of congestive heart failure.
  Japanese Circulation Journal, 1982